Gilde Healthcare

KLIFO provides end-to-end expert capabilities, enabling partners to maximise opportunity, mitigate risks, drive innovation and achieve efficient project advancement. The company offers multidisciplinary consulting and operational solutions spanning all clinical research areas, clinical trial supply, QA, CMC development, regulatory affairs, pharmacovigilance, and the development of pharmaceutical and biotech products and medical devices.

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.

Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.